Vanguard Asset Management
BMRN icon

Vanguard Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vanguard Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.84M Sell
171,983
-302
-0.2% -$16.5K 0.01% 731
2026
Q1 		$9.73M Buy
+172,285
New +$10M 0.01% 674

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Asset Management's BMRN Position: Q2 2026 in Review

Vanguard Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.18% in Q2 2026, selling an estimated $16.5K and leaving 171,983 shares worth $9.84M. The position accounts for 0.01% of the portfolio, ranked #731.

Vanguard Asset Management first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Vanguard Asset Management held 171,983 shares of BioMarin Pharmaceuticals worth $9.84M as of Q2 2026.
  • Vanguard Asset Management sold 302 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $16.5K.
  • BioMarin Pharmaceuticals made up 0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #731 holding.
  • Vanguard Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.